Mahdi Barzegar
Isfahan University of Medical Sciences
Internal medicineDermatologyRetrospective cohort studyPrevalencePediatricsSpectrum disorderCoronavirusPneumoniaDepression (differential diagnoses)DiseaseComorbidityMEDLINEMultiple sclerosisExpanded Disability Status ScaleNeuromyelitis opticaPopulationCoronavirus disease 2019 (COVID-19)In patientRisk factorAnxietyMedicineScopusPandemicGastroenterologyMeta-analysis
39Publications
6H-index
166Citations
Publications 38
Newest
#1Nasim Nehzat (Tehran University of Medical Sciences)H-Index: 5
#2Omid Mirmosayyeb (Tehran University of Medical Sciences)H-Index: 10
Last. Vahid Shaygannejad (IUMS: Isfahan University of Medical Sciences)H-Index: 23
view all 6 authors...
Background. The aim of this observational study is to investigate the efficacy and safety of two approved oral disease-modifying therapies (DMTs) in patients with remitting-relapsing multiple sclerosis (RRMS): dimethyl fumarate (DMF) vs. teriflunomide (TRF). Methods. A total of 159 RRMS patients (82 on TRF and 77 on DMF) were included. The expanded disability status scale (EDSS), confirmed disability improvement (CDI), confirmed disability progression (CDP), and annualized relapse rate (ARR) wer...
Source
#1Fereshteh Ashtari (IUMS: Isfahan University of Medical Sciences)H-Index: 17
#2Akram Ataei (IUMS: Isfahan University of Medical Sciences)H-Index: 2
Last. Marjan Mansurian (IUMS: Isfahan University of Medical Sciences)H-Index: 1
view all 8 authors...
Source
#1Mahdi Barzegar (IUMS: Isfahan University of Medical Sciences)H-Index: 6
#2Soroush Najdaghi (IUMS: Isfahan University of Medical Sciences)
Last. Vahid Shaygannejad (IUMS: Isfahan University of Medical Sciences)H-Index: 23
view all 6 authors...
BACKGROUND We conducted this study to estimated the time of conversion from relapsing-remitting MS (RRMS) to SPMS and its early predictor factors. METHODS In this retrospective study, demographic, clinical, and imaging data from MS patients at diagnosis were extracted. Cox proportional hazards model was used to assess the association between various baseline characteristics and conversion to SPMS. We also assessed the association brtween escalation and early intensive therapy approaches with tra...
Source
Objectives: Olfactory dysfunction is a major comorbidity observed in patients with multiple sclerosis, yet different prevalence rates are reported for it. Therefore, we have designed this systematic review to estimate the pooled prevalence of olfactory dysfunction in patients with MS. To our knowledge, this is the first systematic review and meta-analysis on the prevalence of olfactory dysfunction in MS patients. Method: We searched PubMed, Scopus, EMBASE, Web of Science, ProQuest, and gray lite...
Source
#1Mahdi Barzegar (IUMS: Isfahan University of Medical Sciences)H-Index: 6
#2bagherieh S (IUMS: Isfahan University of Medical Sciences)
Last. Aram Zabeti (UC: University of Cincinnati)H-Index: 4
view all 9 authors...
Background: We conducted this systematic review to identify factors associated with coronavirus disease (COVID-19) susceptibility and outcomes among people with multiple sclerosis (MS). Methods: Available studies from PubMed, Scopus, EMBASE, Web of Science, and gray literature including reference list and conference abstracts were searched from December 1, 2019, through April 12, 2021. We included cross-sectional, case-control, and cohort studies that reported risk factors of contracting COVID-1...
Source
Source
#1Omid MirmosayyebH-Index: 10
Last. Mahdi BarzegarH-Index: 6
view all 7 authors...
ObjectivesDysphagia is a major comorbidity observed in patients with multiple sclerosis, yet different prevalence rates are reported for it. Therefore, we have designed this systematic review to estimate the pooled prevalence of dysphagia in patients with MS. null MethodWe searched PubMed, Scopus, EMBASE, Web of Science, and gray literature including references from the identified studies, reviews studies, and conference abstracts which were published up to February 2021. Articles that were rele...
Source
#1Abdorreza Naser Moghadasi (Tehran University of Medical Sciences)H-Index: 12
#2Omid Mirmosayyeb (Tehran University of Medical Sciences)H-Index: 10
Last. Mahsa Ghajarzadeh (Tehran University of Medical Sciences)H-Index: 16
view all 5 authors...
BACKGROUND: The prevalence of COVID-19 is different in studies conducted in different countries. The aim of this systematic review and meta-analysis is to estimate the pooled prevalence of COVID-19 in patients with MS. METHODS: Two independent researchers independently searched PubMed, Scopus, EMBASE, Web of Science, and google scholar along with gray literature up to April 2021. The search strategy included the MeSH and text words as (((coronavirus OR Wuhan coronavirus OR novel coronavirus OR c...
1 CitationsSource
OBJECTIVE We systematically reviewed the literature on COVID-19 in patients with multiple sclerosis (MS). METHODS We searched PubMed, Scopus, EMBASE, CINAHL, Web of Science, Google Scholar, and World Health Organization database from December 1, 2019, to December 18, 2020. Three conference abstract databases were also searched. We included any types of studies that reported characteristics of patients with MS with COVID-19. RESULTS From an initial 2,679 publications and 3,138 conference abstract...
9 CitationsSource
#1Mahdi Barzegar (IUMS: Isfahan University of Medical Sciences)H-Index: 6
#2Saeed Vaheb (IUMS: Isfahan University of Medical Sciences)H-Index: 3
Last. Vahid Shaygannejad (IUMS: Isfahan University of Medical Sciences)H-Index: 23
view all 6 authors...
Abstract The effect of coronavirus disease (COVID-19) on the risk of relapse in multiple sclerosis (MS) have been unknown. In this retrospective study of 41 relapsing-remitting MS patients, number of relapses in pre-defined at risk-period (ARP) was compared with the previous two years. During the previous two years, a total of 32 attacks was reported, which 5 (15.6%) were during the at-risk period. After adjusting for age and sex, there was an increased risk of attack during ARP compared to the ...
4 CitationsSource